Sierra Oncology (NASDAQ:SRRA – Get Rating) was downgraded by investment analysts at Lifesci Capital from an “outperform” rating to a “market perform” rating in a note issued to investors on Wednesday, Zacks.com reports.
SRRA has been the subject of a number of other reports. Zacks Investment Research upgraded Sierra Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, January 22nd. Jefferies Financial Group cut Sierra Oncology from a “buy” rating to a “hold” rating and raised their target price for the stock from $39.00 to $55.00 in a report on Thursday. Oppenheimer lowered Sierra Oncology from an “outperform” rating to a “market perform” rating and raised their price target for the stock from $45.00 to $55.00 in a research report on Thursday. Finally, HC Wainwright cut shares of Sierra Oncology from a “buy” rating to a “neutral” rating and increased their target price for the stock from $51.00 to $55.00 in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $51.00.
Shares of NASDAQ:SRRA opened at $54.75 on Wednesday. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -7.66 and a beta of 0.57. Sierra Oncology has a 1 year low of $14.91 and a 1 year high of $54.97. The business has a fifty day simple moving average of $33.52 and a 200 day simple moving average of $26.14.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Elmwood Wealth Management Inc. bought a new position in shares of Sierra Oncology during the fourth quarter valued at $25,000. JPMorgan Chase & Co. boosted its holdings in shares of Sierra Oncology by 1,200.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,300 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,200 shares during the last quarter. BlackRock Inc. lifted its holdings in Sierra Oncology by 14.6% during the fourth quarter. BlackRock Inc. now owns 23,445 shares of the biotechnology company’s stock valued at $509,000 after purchasing an additional 2,988 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Sierra Oncology during the fourth quarter valued at approximately $79,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Sierra Oncology by 27.4% in the third quarter. Dimensional Fund Advisors LP now owns 23,097 shares of the biotechnology company’s stock worth $506,000 after buying an additional 4,968 shares in the last quarter.
About Sierra Oncology (Get Rating)
Sierra Oncology, Inc, a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor.
- Get a free copy of the StockNews.com research report on Sierra Oncology (SRRA)
- Lululemon Rises On Wave Of Price Target Increases
- 3 Stellar Steel Stocks to Buy Now
- Is Nvidia (NASDAQ: NVDA) About To Rip Higher?
- The Top Is In For Infosys
- Fasten Your Seatbelts, Fastenal Is About To Move Higher
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.